Baird recently initiated UnitedHealth as outperform, citing the health insurance company as a favorite idea at the firm. The firm views UnitedHealth Group as the most vertically and horizontally integrated Managed Care company, with a $597 price target indicating a potential 20% upside.
Evercore ISI upgraded Okta to outperform from in line after the identity access management company delivered strong F1Q results that exceeded tempered expectations. The upbeat tone following earnings suggests that prior missteps and execution issues are now behind Okta.
Goldman Sachs initiated Abbott Labs as a buy, stating that the company is well positioned for growth. The diversified business model and strong product cycles are expected to sustain top-line growth, with margin expansion driving potential EPS upside.
UBS reiterated Apple as neutral, attributing iPhone pressure in China and the U.S. to continued challenges facing the tech giant. The analysis of April smartphone sell-through data indicates persistent pressure in the two largest smartphone markets.
Piper Sandler downgraded Cava to neutral from overweight following the company’s 1Q24 earnings results. Despite a previously positive outlook, the updated price target of $92 implies only a 4% upside from current levels, leading to a more balanced risk/reward assessment.
Goldman Sachs reiterated its neutral rating on Eli Lilly, raising the price target to $785 per share on updated market forecasts for obesity therapeutics. The new projection indicates potential sales growth for next-generation anti-obesity medications.
Mizuho upgraded PayPal to buy from neutral, highlighting the payment company’s attractive valuation. The stock is trading above its historical level relative to peers, making it a compelling investment opportunity.
Bank of America reiterated its buy rating on Amazon, emphasizing the underappreciated potential of the company’s advertising revenues. The growth of advertising revenues outpacing Gross Merchandise Value could significantly contribute to retail profitability.
Wells Fargo upgraded US Cellular to overweight from equal weight, noting that the company’s sale to T-Mobile could unlock value for shareholders. The wireless sale to T-Mobile is seen as a strategic move that could benefit investors.
Mizuho downgraded First Solar to neutral from buy based on valuation concerns. The stock’s strong pricing power and limited upside potential led to the revised assessment, reflecting a cautious outlook on the company’s performance.
Deutsche Bank upgraded Formula One to buy from hold, citing the racing series’ strong growth outlook and attractive valuation. The company’s position within the industry is seen as favorable for future success.
Wedbush added Cheesecake Factory to the best ideas list, highlighting the stock’s underappreciated potential. The company’s visibility in terms of top- and bottom-line growth sets it apart from competitors.
JPMorgan upgraded Corning to overweight from neutral, citing the company’s EPS upside potential. The favorable market conditions and strategic positioning in key business areas are expected to drive significant earnings growth.
Daiwa reiterated Nvidia as outperform, raising the price target on the stock to $1,325 per share. The company’s strong positioning within the market is seen as a key advantage for future success.
Stifel upgraded International Game Technology to buy from hold, expressing bullish sentiment towards the gambling company. The increased target price reflects a positive outlook on the company’s performance.
Goldman Sachs reiterated its buy rating on Salesforce, acknowledging lower-than-expected results in the latest earnings report. The stock remains a solid investment opportunity despite the minor setbacks.
Redburn Atlantic Equities initiated Insulet as a buy, expressing bullish sentiment towards the insulin and diabetes products company. The expected margin expansion and operating leverage are viewed as key drivers of growth.
Northland upgraded AI company C3.ai to outperform from market perform following strong financial performance. The accelerating subscription growth and demand for genAI products indicate a positive growth trajectory.
Goldman Sachs initiated AstraZeneca, Novartis, and Novo Nordisk as buy, highlighting innovation momentum as a key focus. The buy ratings reflect the potential for future growth and development within the biotech sector.
Bank of America upgraded Datadog to buy from neutral, positioning the stock as best-in-class within the observability market. The company’s potential for share gains and growth within the total addressable market are key factors driving the upgrade.
Guggenheim downgraded Generac to sell from neutral based on valuation concerns. The stock’s recent price increase and limited upside potential led to the revised assessment, reflecting caution towards the company’s performance in the near future.